首页 国际期刊 医学期刊 期刊详情(非官网)
400-808-1701

Experimental Hematology & Oncology

Experimental Hematology & Oncology杂志,由BioMed Central出版,于2012年创刊,1 issue/year,出版语言English,ISSN:2162-3619,E-ISSN:2162-3619。

投稿咨询
Experimental Hematology & Oncology
Experimental Hematology & Oncology
Experimental Hematology & Oncology
SCI SCIE

杂志介绍

JCR分区
Q1
中科院分区
1区
影响因子
17.5
CiteScore
19.6
期刊收录
SCI、SCIE

Experimental Hematology & Oncology(中文译名:《实验血液学和肿瘤学》),ISSN:2162-3619,EISSN:2162-3619,是BioMed Central出版的国际性学术期刊,创刊于2012年,以1 issue/year形式稳定发行,2026年总发文量约92篇。该刊采用OA开放访问,学科归属为Medicine - Oncology。该刊是医学、肿瘤学领域的国际权威刊物,已被SCI(科学引文索引)、SCIE(科学引文索引扩展版)等国际主流学术数据库收录。2026年期刊影响因子达17.5,2025年期刊CiteScore为19.6,2025年期刊自引率约5.7%,在中科院期刊分区体系中位列医学大类1区TOP 期刊,在所属学科领域具备高学术影响力与国际认可度。Experimental Hematology & Oncology长期聚焦医学、肿瘤学及相关产业的技术应用前沿,平均审稿周期6 Weeks,审稿流程高效稳定。在稿件录用评判中,该刊将创新性与前沿性作为核心遴选标准,重点收录能够对医学、肿瘤学领域的落地与发展产生实质性推动价值的研究成果。

从全球发文格局来看,USACHINA MAINLAND、Iran、Italy、Canada、France、Norway等为核心发文国家与地区;ZHENGZHOU UNIVERSITYHUAZHONG UNIVERSITY OF SCIENCE & TECHNOLOGY、LOMA LINDA UNIVERSITY、UNIVERSITY OF CALIFORNIA SYSTEM、INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)、NEW YORK MEDICAL COLLEGE、ZHEJIANG UNIVERSITY等高校与科研机构是期刊的主要发文单位。

期刊评价

名词解释:

影响因子(Impact Factor, IF):指该期刊前两年发表的文章,在第三年的平均被引用次数。它反映了期刊的近期平均影响力和热度。

中科院分区:中科院分区表是国内主流的学术期刊分级评价工具,核心意义是建立跨学科可比的统一评价标尺,为职称评审、学位授予、科研立项等科研管理工作提供标准化量化依据,同时帮助科研人员筛选优质期刊、规避学术风险,适配国内本土化的科研评价需求。

期刊分区表

《新锐期刊分区表》(2026年3月发布)

大类学科 小类学科 Top期刊 综述期刊
医学
1区
ONCOLOGY 肿瘤学 HEMATOLOGY 血液学
1区 1区
是 否

期刊分区表(2025年3月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
2区
HEMATOLOGY 血液学 ONCOLOGY 肿瘤学
2区 2区
否 否

期刊分区表(2023年12月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
1区
HEMATOLOGY 血液学 ONCOLOGY 肿瘤学
2区 2区
否 否

JCR分区

2025-2026年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:HEMATOLOGY SCIE Q1 5 / 103

95.6

学科:ONCOLOGY SCIE Q1 19 / 333

94.4

学科:HEMATOLOGY SCIE Q1 6 / 103

94.66

学科:ONCOLOGY SCIE Q1 28 / 333

91.74

2023-2024年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:HEMATOLOGY SCIE Q1 9 / 97

91.2

学科:ONCOLOGY SCIE Q1 32 / 322

90.2

学科:HEMATOLOGY SCIE Q1 13 / 97

87.11

学科:ONCOLOGY SCIE Q1 36 / 322

88.98


中国学者近期发文

1
Decoding the spatiotemporal characteristics of ferroptosis: reshaping tumour therapeutic strategie

Author:Song, Lizhou; Shu, Yue; Zhou, Tian; Wang, Yi; Zhang, Haoling; Liao, Yan; Zhu, Chenglong; Zhang, Wangzheqi; Zou, Zui

Journal: EXPERIMENTAL HEMATOLOGY & ONCOLOGY. 2026; Vol. 15, Issue 1, pp. -. DOI: 10.1186/s40164-026-00773-5

2
Novel non-viral in vivo CAR-T therapies: latest updates from the 2025 ASH annual meeting (vol 15, 34, 2026

Author:Xue, Bin; Liu, Yifan; Liang, Aibin; Zhang, Wenjun

Journal: EXPERIMENTAL HEMATOLOGY & ONCOLOGY. 2026; Vol. 15, Issue 1, pp. -. DOI: 10.1186/s40164-026-00772-6

3
The novel retinoid WYC-209 sensitizes multiple myeloma to carfilzomib via epigenetically upregulating ZMYND

Author:Xu, Jiaxuan; Yan, Jie; Zhang, Haoyu; Dong, Jiahui; Wu, Yue; Qian, Jiajia; Zhao, Quan; Dong, Xiaoqing; Chen, Bing

Journal: EXPERIMENTAL HEMATOLOGY & ONCOLOGY. 2026; Vol. 15, Issue 1, pp. -. DOI: 10.1186/s40164-026-00770-8

4
Functional xenogeneic hematopoietic cells maintaining donor-dominant identity and immune tolerance enable therap

Author:Xiong, Shumin; Zhou, Ren; Wei, Chuijin; Wang, Xiaomin; Tang, Yunhan; Dong, Liaoliao; Yu, Ping; Pei, Duanqing; Chen, Zhu; Chen, Sai-Juan; Cheng, Lin

Journal: EXPERIMENTAL HEMATOLOGY & ONCOLOGY. 2026; Vol. 15, Issue 1, pp. -. DOI: 10.1186/s40164-026-00767-3

5
Novel non-viral in vivo CAR-T therapies: latest updates from the 2025 ASH annual meetin

Author:Xue, Bin; Liu, Yifan; Liang, Aibin; Zhang, Wenjun

Journal: EXPERIMENTAL HEMATOLOGY & ONCOLOGY. 2026; Vol. 15, Issue 1, pp. -. DOI: 10.1186/s40164-026-00765-5

6
Prospects and advances of PROTAC in the treatment of hematologic malignancie

Author:Wang, Xinyang; Zhang, Ming; Mei, Heng

Journal: EXPERIMENTAL HEMATOLOGY & ONCOLOGY. 2026; Vol. 15, Issue 1, pp. -. DOI: 10.1186/s40164-026-00759-3

7
Systematic and precise interventions for KRAS-mutant cancer

Author:Liang, Jinghui; Wu, Junxi; Zhang, Yuan; Wang, Hongyu; Zheng, Yiyang; He, Qing

Journal: EXPERIMENTAL HEMATOLOGY & ONCOLOGY. 2026; Vol. 15, Issue 1, pp. -. DOI: 10.1186/s40164-026-00763-7

8
Efficacy and safety of ruxolitinib for graft-versus-host disease prophylaxis in patients with aplastic anemia undergoing PBSC-only allogeneic stem cell transplantation: a prospective phase II stud

Author:Zhang, Xiaoyu; Pan, Lulu; Zhao, Yanhong; Ma, Runzhi; Zhang, Lining; Zhang, Ying; Li, Gang; Zhai, Weihua; Ma, Qiaoling; Pang, Aiming; Yang, Donglin; Feng, Sizhou; Zhang, Ping; He, Yi; Qin, Guoyou; Jiang, Erlie; Han, Mingzhe

Journal: EXPERIMENTAL HEMATOLOGY & ONCOLOGY. 2026; Vol. 15, Issue 1, pp. -. DOI: 10.1186/s40164-026-00753-9

9
Tertiary lymphoid structures correlate with reduced recurrence risk and enhanced antitumor immunity in esophageal squamous cell carcinoma with pathologic non-complete response to neoadjuvant chemoimmunotherap

Author:Wo, Yang; Lu, Tong; Yang, Zijiang; Li, Xiongfei; Wang, Zheyi; Peng, Yizhou; Shen, Xuxia; Hou, Feng; Jiao, Wenjie; Sun, Yihua

Journal: EXPERIMENTAL HEMATOLOGY & ONCOLOGY. 2026; Vol. 15, Issue 1, pp. -. DOI: 10.1186/s40164-026-00748-6

10
Matrix stiffness induces Ca2+-DCLK1-PIP5K1A mechanotransduction as a context-specific amplifier in pancreatic cancer progression and chemotherapy resistanc

Author:Zhang, Haoxiang; Zhao, Chuanbing; Chen, Jiaoshun; Hu, Xiaoqing; Bai, Jianwei; He, Long; Deng, Zanglong; Yin, Tao

Journal: EXPERIMENTAL HEMATOLOGY & ONCOLOGY. 2026; Vol. 15, Issue 1, pp. -. DOI: 10.1186/s40164-026-00756-6


在线咨询

Experimental Hematology & Oncology

国际简称:EXP HEMATOL ONCOL参考译名:实验血液学和肿瘤学

年发文量:92 CiteScore:19.6 是否预警:否 Gold OA文章占比:100.00% 研究类文章占比:63.04%

杂志社联系方式:CAMPUS, 4 CRINAN ST, LONDON, ENGLAND, N1 9XW

Experimental Hematology & Oncology